Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Commentary: Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis
Alexander Egeberg, MD, PhD, DMSc
Bispebjerg Hospital
Copenhagen, Denmark
PUBLICATION
Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis. Yiu ZZN, Becher G, Kirby B, et al. JAMA Dermatol. 2022 Jul 6:e222909. doi: 10.1001/jamadermatol.2022.2909. Epub ahead of print. PMID: 35791876; PMCID: PMC9260644.
Why this article was chosen
Real-world evidence studies become crucial to achieving the evidence needed in clinical practice. But how are data evaluated in the complexity of the real world?
Commentary
In recent years, clinical trials of drugs, such as interleukin (IL)-17 and IL-23 inhibitors, have shown remarkable levels of sustained long-term clearance of psoriasis. However, a fundamental limitation of clinical trials is that the patients included in such trials are not always representative of patients seen in daily clinical practice. Only about one-third of “real-life” patients are eligible for inclusion in a clinical trial. Moreover, comorbid diseases, physician behaviors, dose modifications, regional guidelines, payer policies, and prescribed co-medication may all influence the effectiveness and safety of biologics in daily clinical practice.
In daily practice, loss of response over time is often observed. Although the reasons are still not fully understood, this degree of “biologic fatigue” appears to differ between the different biologics. The term “drug survival” refers to the probability that a patient will remain on treatment and is a critical proxy measure of effectiveness in real-life settings.
The present study examined drug survival among 16,122 treatment courses of biologic therapy with either guselkumab, ixekizumab, secukinumab, ustekinumab, or adalimumab, using United Kingdom registry data. The authors found that guselkumab had the highest drug survival concerning effectiveness and safety. Notably, the authors also found that the effect of biologic therapy was modified by factors such as the presence of psoriatic arthritis, prior exposure to biologic therapy, current nail psoriasis, and ethnicity, thus highlighting that “one size does not fit all” when it comes to treating psoriasis.
Significantly, however, treatment patterns may change over time, and a patient is more likely to, e.g., discontinue adalimumab in the present day compared with twenty years ago, when alternatives were much more limited. The study adds to the growing list of real-world studies suggesting that novel biologics, such as the IL-23 inhibitor guselkumab, have a higher drug survival in psoriasis. Still, there remains an essential need for “personalized evidence,” i.e., predictors showing which patient profiles will benefit the most from a specific biologic.
Categories
Recent Posts
Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Albert Duvetorp, MD, PhD
Medical Adherence in Topical Agents in the Context of Psoriasis Patients
Commentary: The Next Era of Opportunity in Psoriasis: Spatial Transcriptomics
Also Read
Commentary: The Next Era of Opportunity in Psoriasis: Spatial Transcriptomics
Nicole Ward explores groundbreaking psoriatic disease research methods published in recent literature. Discover how Spatial Transcriptomics and Single Cell Sequencing unveil new cellular players and pathways, opening doors to novel drug targets and advancing psoriasis research and medicine.
Commentary: Efficacy and Safety of Oral Roflumilast for Moderate to Severe Psoriasis—A Randomized Controlled Trial (PSORRO)
In this blog post, we examine the findings of a randomized controlled trial investigating the efficacy and safety of oral roflumilast for patients with moderate to severe psoriasis. Discover how this targeted phosphodiesterase-4 inhibitor reduces pro-inflammatory cytokines and improves psoriasis symptoms. Learn about the study’s methodology, key results, and the potential of oral roflumilast as a cost-saving alternative for psoriasis treatment. Find out how this convenient and affordable oral option could benefit patients without access to effective psoriasis therapies.
Commentary: Preclinical and Clinical Evidence for Suppression of Alcohol Intake by Apremilast
A host of factors is important to consider in the personalized treatment of psoriasis. It is advantageous if a treatment is effective in psoriasis and has beneficial effects on associated conditions. This recent literature publication has highlighted that apremilast, beyond its anti-psoriatic properties, positively impacts excessive alcohol consumption. Read the expert opinion of IPC Board Member Johann Gudjonsson, MD, PhD.
Subscribe to the IPC Newsletter